The FDA-approved imaging agent for detecting coronary artery disease gained Medicare and Medicaid coverage starting April 1.

GEHC's latest commercial launch of Flyrcado and the grant of pass-through status by CMS aim to serve a wider patient pool across the United States.

The much-anticipated Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging agent for the detection of coronary artery disease, ...

The much-anticipated Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging agent for the detection of coronary artery ...

GE HealthCare Technologies Inc. GEHC recently announced the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the ongoing American College of Cardiology (ACC) Annual Scientific Session & Expo.

Introduced at ACC.25, the Revolution Vibe CT system includes Unlimited One-Beat Cardiac imaging and combines with GE HealthCare’s ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and Effortless ...